Form 4: Verona Pharma's General Counsel, Andrew Fisher, Executes Option and Sells Shares Under 10b5-1 Plan

Andrew Fisher, General Counsel of Verona Pharma, exercised share options and sold 80,000 ordinary shares (represented by ADSs) under a pre-arranged 10b5-1 trading plan.

Summary

• On May 15, 2025, Andrew Fisher, the General Counsel of Verona Pharma, exercised options to acquire 80,000 ordinary shares at a price of $2.113 per share.
• Simultaneously, Fisher sold 80,000 ordinary shares at an average price of $8.57 per share, with individual sales ranging from $8.3863 to $8.6913.
• The sale was conducted under a Rule 10b5-1 plan established on January 15, 2025.
• Following these transactions, Fisher directly owns 359,999 ordinary shares.
• This includes 300,000 ordinary shares underlying Restricted Share Units (RSUs), 59,992 ordinary shares underlying ADSs, and 7 ordinary shares.
• Fisher also holds options to purchase 2,320,000 ordinary shares, which vest in installments.

Sentiment

Score: 5

Explanation: The document reflects routine transactions (option exercise and share sale under a pre-existing plan) and doesn't inherently indicate positive or negative sentiment regarding the company's prospects.

Industry Context

Executive share sales are common and often pre-planned using 10b5-1 plans to avoid insider trading accusations. The sale by Verona Pharma's General Counsel is likely part of their personal financial management strategy.

Stakeholder Impact

• The share sale may have a minor dilutive effect on existing shareholders.
• The transactions do not appear to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Verona Pharma, Andrew Fisher, Form 4, Share Sale, Option Exercise, 10b5-1 Plan, ADS, Ordinary Shares, General Counsel